2/2
06:20 am
cogt
Cogent Biosciences FDA Milestones Put Bezuclastinib And Valuation In Focus [Yahoo! Finance]
Medium
Report
Cogent Biosciences FDA Milestones Put Bezuclastinib And Valuation In Focus [Yahoo! Finance]
2/2
04:32 am
cogt
Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD) [Yahoo! Finance]
Medium
Report
Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD) [Yahoo! Finance]
2/1
02:28 am
cogt
Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M [Yahoo! Finance]
Medium
Report
Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M [Yahoo! Finance]
1/31
01:33 am
cogt
Cogent Biosciences (NASDAQ:COGT) was downgraded by analysts at
Wall Stre
Medium
Report
Cogent Biosciences (NASDAQ:COGT) was downgraded by analysts at
Wall Stre
1/27
08:33 am
cogt
Cogent Biosciences announcse U.S. BTD for bezuclastinib [Yahoo! Finance]
Low
Report
Cogent Biosciences announcse U.S. BTD for bezuclastinib [Yahoo! Finance]
1/26
08:00 am
cogt
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
Low
Report
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
1/21
11:22 am
cogt
Cogent Biosciences (COGT) Is Up 13.1% After FDA RTOR Nod For Bezuclastinib Combo - Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Cogent Biosciences (COGT) Is Up 13.1% After FDA RTOR Nod For Bezuclastinib Combo - Has The Bull Case Changed? [Yahoo! Finance]
1/21
09:05 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $55.00 price target on the stock.
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $55.00 price target on the stock.
1/20
08:00 am
cogt
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
Low
Report
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
1/12
08:00 am
cogt
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
Low
Report
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
1/11
03:21 pm
cogt
Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge [Yahoo! Finance]
Low
Report
Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge [Yahoo! Finance]
1/11
01:26 am
cogt
H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) [Yahoo! Finance]
Low
Report
H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) [Yahoo! Finance]
1/9
06:10 am
cogt
Cogent Biosciences (NASDAQ:COGT) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Low
Report
Cogent Biosciences (NASDAQ:COGT) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/6
08:11 am
cogt
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/6
08:00 am
cogt
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
1/6
07:07 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/30
08:00 am
cogt
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
Low
Report
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
12/28
10:21 am
cogt
JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update [Yahoo! Finance]
Low
Report
JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update [Yahoo! Finance]
12/20
01:30 am
cogt
Cogent Biosciences (NASDAQ:COGT) was upgraded by analysts at
Wall Street
Low
Report
Cogent Biosciences (NASDAQ:COGT) was upgraded by analysts at
Wall Street
12/19
11:38 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $67.00. They now have an "overweight" rating on the stock.
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $67.00. They now have an "overweight" rating on the stock.
12/15
06:13 pm
cogt
Cogent Biosciences: Time For A Pause [Seeking Alpha]
Low
Report
Cogent Biosciences: Time For A Pause [Seeking Alpha]
12/8
12:13 pm
cogt
Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/8
11:41 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
12/8
07:30 am
cogt
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Low
Report
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
12/6
09:30 am
cogt
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
Medium
Report
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)